Biocytogen

Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. 

For more information, please visit www.biocytogen.com.